Amlodipine/Lisinopril Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Amlodipine/Lisinopril Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 23 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Amlodipine/Lisinopril can convert its Small molecule drug profile and ACE x L-type calcium channel biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Amlodipine/Lisinopril (query alias: Amlodipine/Lisinopril) |
|---|---|
| Modality / target | Small molecule drug; ACE x L-type calcium channel; ACE inhibitors, L-type calcium channel blockers |
| Highest global status | NDA/BLA |
| Originator | Sichuan Shangrui Biopharmaceutical Co., Ltd., Sichuan Medco Pharmaceutical Stock Co., Ltd. |
| Active developers | Sichuan Medco Pharmaceutical Stock Co., Ltd., Sichuan Shangrui Biopharmaceutical Co., Ltd. |
The MCP disease footprint includes no disclosed indication. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| ChiCTR2600127558 | Phase 4 | Completed | 60 | msSBP |
| NCT07704684 | Phase 3 | Completed | 376 | The baseline change in mean seated systolic blood pressure (msSBP) |
| NCT07704697 | Phase 3 | Completed | 346 | The baseline change in mean seated systolic blood pressure (msSBP) |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
BLOCKade of Calcium Channels and Beta Adrenergic Receptors for the Treatment of Hypertension in Heart Failure With Preserved Ejection Fraction (BLOCK HFpEF) Trial
Phase 4; n=50; evaluation: not stated. Reported fields: Difference in Home Systolic Blood Pressure(Mean) = 134.5 mm Hg (Standard Deviation, 17.2); Difference in Home Systolic Blood Pressure(Mean): Mean Difference (Final Values) = -3.8(95% CI, -6.8 to -0.7), P-Value = 0.017; Difference in Home Systolic Blood Pressure(Mean) = 130.7 mm Hg (Standard Deviation, 12.4)
Low Achieved Systolic Blood Pressure Related to Kidney Protection in Diabetic and Non-Diabetic High-Risk Hypertensive Patients
Phase 3; n=13903; evaluation: Positive. Reported fields: ESKD(at SBP 130-139 mmHg): HR = 0.442(95.0% CI, 0.196 - 1.0), P-Value = 0.05; ESKD(at SBP 130-139 mmHg): HR = 0.442(95.0% CI, 0.196 - 1.0), P-Value = 0.05
Characterization of Arterial Hypertension and Efficacy of Blood-pressure Lowering Therapy at Different Altitudes Above Sea Level
Phase 4; n=166; evaluation: not stated. Reported fields: -; Change is 24-hour Systolic Blood Pressure From Baseline to 4 Weeks(Mean) = -5.9 mmHg (Standard Deviation, 8.4); -
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Amlodipine/Lisinopril addresses its disclosed development indications. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2026-04-15 | Pangea Pharmaceuticals to commercialize Brillian Pharma’s of Sdamlo (amlodipine for oral solution) in the US | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 23 July 2026. Counts and status fields may change as source records update.
